Skip to content

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02281136
Enrollment
29
Registered
2014-11-03
Start date
2014-12-31
Completion date
2015-04-30
Last updated
2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratosis, Actinic

Keywords

Actinic keratosis

Brief summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

Interventions

20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

DEVICEBLU-U

10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2

Sponsors

DUSA Pharmaceuticals, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 6 Grade 1/2 AKs on one upper extremity AND * At least 12 Grade 1/2 AKs on the OTHER upper extremity

Exclusion criteria

* Pregnancy * history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis * lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area * Body Mass Index (BMI) \> 32.0 kg/m2 * skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy * significant blood loss within 60 days or donated blood/plasma within 72 hours prior to Visit 2 (Baseline) * tested positive at screening for human immunodeficiency virus (HIV) or was known to be seropositive for HIV * a history of lead poisoning or a history of a significant exposure to lead or a screening lead level above 6μg/dl * tested positive at screening for hepatitis B surface antigen, hepatitis C antibody or had a history of a positive result * positive drug screen at Screening * Screening safety labs are clinically significant in the opinion of the investigator * major surgery within 30 days prior to Visit 2 (Baseline) or plans to have surgery during the study * Subject is immunosuppressed * currently enrolled in an investigational drug or device study * has received an investigational drug or been treated with an investigational device within 30 days prior to Visit 2 (Baseline) * known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol) * use of the following topical preparations on the extremities to be treated: * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment * Cryotherapy within 2 weeks of initiation of treatment * Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment * use of systemic retinoid therapy within 6 months of initiation of treatment

Design outcomes

Primary

MeasureTime frameDescription
Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA1 dayMaximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples wiere taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16 and 24 hours following study medication application.
Time at Which Cmax is Attained (Tmax) for ALA1 dayTime of the maximum baseline corrected plasma concentration for ALA measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16 and 24 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.
AUCt0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24 hours post-doseAUCt is the area under the baseline corrected plasma concentration-time profile up to the last quantifiable/non-negative plasma concentration
The Terminal Exponential Half-life (T1/2,z)1 dayThe terminal slope will be calculated by linear least squares regression of the log plasma concentration-time data. The terminal exponential half-life (T1/2,z) will be calculated as 0.693 divided by the absolute value of slope.

Secondary

MeasureTime frameDescription
Stinging/BurningBaselineSTINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable
HyperpigmentationBaselineHYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas
OOZING/VESICULATION/CRUSTINGBaselineOOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above
Scaling and DrynessBaselineSCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling
HypopigmentationBaselineHYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas
ErythemaBaselineErythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema
EdemaBaselineEDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Countries

United States

Participant flow

Participants by arm

ArmCount
Levulan Kerastick
20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment Aminolevulinic Acid (ALA): 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light BLU-U: 10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
29
Total29

Baseline characteristics

CharacteristicLevulan Kerastick
Age, Continuous67.7 years
STANDARD_DEVIATION 8.8
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
29 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Gender
Female
6 Participants
Gender
Male
23 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
29 Participants
Region of Enrollment
United States
29 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
1 / 29
serious
Total, serious adverse events
0 / 29

Outcome results

Primary

AUCt

AUCt is the area under the baseline corrected plasma concentration-time profile up to the last quantifiable/non-negative plasma concentration

Time frame: 0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24 hours post-dose

ArmMeasureValue (GEOMETRIC_MEAN)Dispersion
Levulan KerastickAUCt282.1 ng*hr/mLGeometric Coefficient of Variation 163
Primary

Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA

Maximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples wiere taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16 and 24 hours following study medication application.

Time frame: 1 day

ArmMeasureValue (GEOMETRIC_MEAN)Dispersion
Levulan KerastickMaximum Baseline Corrected Plasma Concentration (Cmax) for ALA79.85 ng/mLGeometric Coefficient of Variation 221.7
Primary

The Terminal Exponential Half-life (T1/2,z)

The terminal slope will be calculated by linear least squares regression of the log plasma concentration-time data. The terminal exponential half-life (T1/2,z) will be calculated as 0.693 divided by the absolute value of slope.

Time frame: 1 day

Population: T1/2,z could not be determined in 4 subjects

ArmMeasureValue (GEOMETRIC_MEAN)Dispersion
Levulan KerastickThe Terminal Exponential Half-life (T1/2,z)4.602 hoursGeometric Coefficient of Variation 78.83
Primary

Time at Which Cmax is Attained (Tmax) for ALA

Time of the maximum baseline corrected plasma concentration for ALA measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16 and 24 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.

Time frame: 1 day

ArmMeasureValue (MEDIAN)
Levulan KerastickTime at Which Cmax is Attained (Tmax) for ALA2 hours
Secondary

Edema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickEdemaGrade 029 participants
Levulan KerastickEdemaGrade 10 participants
Levulan KerastickEdemaGrade 20 participants
Levulan KerastickEdemaGrade 30 participants
Levulan KerastickEdemaGrade 40 participants
Secondary

Edema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickEdemaGrade 30 participants
Levulan KerastickEdemaGrade 40 participants
Levulan KerastickEdemaGrade 029 participants
Levulan KerastickEdemaGrade 10 participants
Levulan KerastickEdemaGrade 20 participants
Secondary

Edema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame: 24 hours after PDT #1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickEdemaGrade 14 participants
Levulan KerastickEdemaGrade 22 participants
Levulan KerastickEdemaGrade 30 participants
Levulan KerastickEdemaGrade 022 participants
Levulan KerastickEdemaGrade 40 participants
Secondary

Edema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame: 5 Minutes after PDT

ArmMeasureGroupValue (NUMBER)
Levulan KerastickEdemaGrade 32 participants
Levulan KerastickEdemaGrade 40 participants
Levulan KerastickEdemaGrade 022 participants
Levulan KerastickEdemaGrade 13 participants
Levulan KerastickEdemaGrade 22 participants
Secondary

Erythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickErythemaGrade 16 participants
Levulan KerastickErythemaGrade 023 participants
Levulan KerastickErythemaGrade 20 participants
Levulan KerastickErythemaGrade 30 participants
Levulan KerastickErythemaGrade 40 participants
Secondary

Erythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickErythemaGrade 012 participants
Levulan KerastickErythemaGrade 17 participants
Levulan KerastickErythemaGrade 210 participants
Levulan KerastickErythemaGrade 30 participants
Levulan KerastickErythemaGrade 40 participants
Secondary

Erythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame: 24 hours after PDT #1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickErythemaGrade 04 participants
Levulan KerastickErythemaGrade 10 participants
Levulan KerastickErythemaGrade 29 participants
Levulan KerastickErythemaGrade 313 participants
Levulan KerastickErythemaGrade 42 participants
Secondary

Erythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame: 5 Minutes after PDT

ArmMeasureGroupValue (NUMBER)
Levulan KerastickErythemaGrade 00 participants
Levulan KerastickErythemaGrade 10 participants
Levulan KerastickErythemaGrade 27 participants
Levulan KerastickErythemaGrade 319 participants
Levulan KerastickErythemaGrade 43 participants
Secondary

Hyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHyperpigmentationGrade 06 participants
Levulan KerastickHyperpigmentationGrade 114 participants
Levulan KerastickHyperpigmentationGrade 26 participants
Levulan KerastickHyperpigmentationGrade 33 participants
Levulan KerastickHyperpigmentationGrade 40 participants
Secondary

Hyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHyperpigmentationGrade 07 participants
Levulan KerastickHyperpigmentationGrade 114 participants
Levulan KerastickHyperpigmentationGrade 25 participants
Levulan KerastickHyperpigmentationGrade 33 participants
Levulan KerastickHyperpigmentationGrade 40 participants
Secondary

Hyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame: 24 hours after PDT

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHyperpigmentationGrade 06 participants
Levulan KerastickHyperpigmentationGrade 114 participants
Levulan KerastickHyperpigmentationGrade 24 participants
Levulan KerastickHyperpigmentationGrade 34 participants
Levulan KerastickHyperpigmentationGrade 40 participants
Secondary

Hypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHypopigmentationGrade 23 participants
Levulan KerastickHypopigmentationGrade 010 participants
Levulan KerastickHypopigmentationGrade 116 participants
Levulan KerastickHypopigmentationGrade 30 participants
Levulan KerastickHypopigmentationGrade 40 participants
Secondary

Hypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHypopigmentationGrade 08 participants
Levulan KerastickHypopigmentationGrade 121 participants
Levulan KerastickHypopigmentationGrade 20 participants
Levulan KerastickHypopigmentationGrade 30 participants
Levulan KerastickHypopigmentationGrade 40 participants
Secondary

Hypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame: 24 hours post PDT#1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickHypopigmentationGrade 40 participants
Levulan KerastickHypopigmentationGrade 09 participants
Levulan KerastickHypopigmentationGrade 118 participants
Levulan KerastickHypopigmentationGrade 20 participants
Levulan KerastickHypopigmentationGrade 31 participants
Secondary

OOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 028 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 11 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 20 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 30 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 40 participants
Secondary

OOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 029 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 10 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 20 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 30 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 40 participants
Secondary

OOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame: 24 hours after PDT #1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 027 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 11 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 20 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 30 participants
Levulan KerastickOOZING/VESICULATION/CRUSTINGGrade 40 participants
Secondary

Scaling and Dryness

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickScaling and DrynessGrade 025 participants
Levulan KerastickScaling and DrynessGrade 11 participants
Levulan KerastickScaling and DrynessGrade 23 participants
Levulan KerastickScaling and DrynessGrade 30 participants
Levulan KerastickScaling and DrynessGrade 40 participants
Secondary

Scaling and Dryness

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame: 24 hours after PDT #1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickScaling and DrynessGrade 020 participants
Levulan KerastickScaling and DrynessGrade 17 participants
Levulan KerastickScaling and DrynessGrade 21 participants
Levulan KerastickScaling and DrynessGrade 30 participants
Levulan KerastickScaling and DrynessGrade 40 participants
Secondary

Scaling and Dryness

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickScaling and DrynessGrade 40 participants
Levulan KerastickScaling and DrynessGrade 019 participants
Levulan KerastickScaling and DrynessGrade 19 participants
Levulan KerastickScaling and DrynessGrade 21 participants
Levulan KerastickScaling and DrynessGrade 30 participants
Secondary

Stinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame: Week 4

ArmMeasureGroupValue (NUMBER)
Levulan KerastickStinging/BurningGrade 029 participants
Levulan KerastickStinging/BurningGrade 10 participants
Levulan KerastickStinging/BurningGrade 20 participants
Levulan KerastickStinging/BurningGrade 30 participants
Secondary

Stinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame: Baseline

ArmMeasureGroupValue (NUMBER)
Levulan KerastickStinging/BurningGrade 10 participants
Levulan KerastickStinging/BurningGrade 20 participants
Levulan KerastickStinging/BurningGrade 029 participants
Levulan KerastickStinging/BurningGrade 30 participants
Secondary

Stinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame: 24 hours after PDT #1

Population: One subject did not have assessment performed

ArmMeasureGroupValue (NUMBER)
Levulan KerastickStinging/BurningGrade 018 participants
Levulan KerastickStinging/BurningGrade 19 participants
Levulan KerastickStinging/BurningGrade 21 participants
Levulan KerastickStinging/BurningGrade 30 participants
Secondary

Stinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame: During PDT

ArmMeasureGroupValue (NUMBER)
Levulan KerastickStinging/BurningGrade 00 participants
Levulan KerastickStinging/BurningGrade 10 participants
Levulan KerastickStinging/BurningGrade 219 participants
Levulan KerastickStinging/BurningGrade 310 participants
Secondary

Stinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame: 5 Minutes after PDT

ArmMeasureGroupValue (NUMBER)
Levulan KerastickStinging/BurningGrade 00 participants
Levulan KerastickStinging/BurningGrade 121 participants
Levulan KerastickStinging/BurningGrade 27 participants
Levulan KerastickStinging/BurningGrade 31 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026